Mindmed To Conduct 15-To-1 Reverse Split To Meet Nasdaq Listing Requirements
In a classic Canadian small cap move, Mind Medicine (NEO: MMED) last night announced that it’s directors have approved a
Read more
MindMed
MindMed Reveals Favorable Results From Phase 1 Trial Of Drug Candidate For Opioid Withdrawal Treatment
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the topline results from the phase 1 clinical
Read more
MindMed Presents Positive Data Studying LSD In Treating Anxiety Disorders
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today that its top collaborators have released positive topline
Read more
MindMed Declares US$93.0 Million Net Loss, US$133.5 Million Cash Balance For 2021
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced this morning its financial results for 2021. The biotech
Read more
Mind Medicine CFO Quits Ahead Of Release Of 2021 Financial Results
It’s always a positive sign when a chief financial officer resigns the last business day before annual filings are to
Read more
Mind Medicine Sees Final Co-Founder Leave The Company
Mind Medicine (NEO: MMED) appears to now be fully under new management. On Friday evening, after the close of markets,
Read more
MindMed Concludes Phase 1 Clinical Trial Of Psychedelic Derivative Drug For Opioid Use Disorder
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, has recently concluded the phase 1 clinical trial for its
Read more
Mind Medicine Closes The Year Out With Further Management Departures
Mind Medicine (NEO: MMED) has seen further management departures, following the departure of its CEO this past summer. Classified as
Read more
Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study
Mind Medicine (NEO: MMED) this morning indicated that things are not going quite to plan with an IND submission for
Read more
MindMed Launches R(-)-MDMA Program For Autism Spectrum Disorder Symptoms
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, recently launched a program to develop R(-)-MDMA for treating symptoms
Read more